[Dose optimization: an individualized treatment strategy for chronic myeloid leukemia].
作者信息
Chen Y L, Zou J, Zhang Y L, Li W M
机构信息
Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):436-440. doi: 10.3760/cma.j.issn.0253-2727.2022.05.017.
Abstract
摘要
相似文献
1
[Dose optimization: an individualized treatment strategy for chronic myeloid leukemia].[剂量优化：慢性髓性白血病的个体化治疗策略]
Zhonghua Xue Ye Xue Za Zhi. 2022 May 14;43(5):436-440. doi: 10.3760/cma.j.issn.0253-2727.2022.05.017.
2
Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.伊马替尼治疗的慢性髓性白血病患者快速转化为慢性粒单核细胞白血病
Leukemia. 2016 Nov;30(11):2275-2279. doi: 10.1038/leu.2016.218. Epub 2016 Aug 2.
3
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.甲磺酸伊马替尼用于慢性髓性白血病：一线治疗及长期疗效
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
4
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.慢性髓性白血病儿童和青少年间歇性伊马替尼（ON/OFF方案）的结果与转归
Br J Haematol. 2020 Mar;188(6):e101-e105. doi: 10.1111/bjh.16388. Epub 2020 Feb 22.
5
Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.伊马替尼治疗慢性髓性白血病期间的早幼粒细胞白血病急变期
Turk J Haematol. 2015 Jun;32(2):193-4. doi: 10.4274/tjh.2014.0211.
6
The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
Acta Haematol. 2016;135(3):131-2. doi: 10.1159/000441411. Epub 2015 Nov 5.
7
Aggregates of Pseudogaucher Cells in a Pediatric Patient With Chronic Myeloid Leukemia.一名慢性髓性白血病儿科患者中的假性戈谢细胞聚集物。
J Pediatr Hematol Oncol. 2021 Aug 1;43(6):224-225. doi: 10.1097/MPH.0000000000002215.
8
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.伊马替尼——2015年用于慢性髓性白血病一线治疗的新型酪氨酸激酶抑制剂。
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
9
Imatinib-Associated Pneumocystis jirovecii Pneumonia in a Patient With Chronic Myeloid Leukemia.一名慢性髓性白血病患者发生伊马替尼相关的耶氏肺孢子菌肺炎
Am J Ther. 2020 Jul/Aug;27(4):e406-e409. doi: 10.1097/MJT.0000000000000963.
10
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.慢性髓性白血病使用通用型伊马替尼的持续性：一项匹配队列研究。
Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10.
本文引用的文献
1
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.基于治疗药物监测的达沙替尼剂量优化可降低慢性髓性白血病患者胸腔积液发生率。
Br J Haematol. 2021 Jul;194(2):393-402. doi: 10.1111/bjh.17654. Epub 2021 Jun 30.
2
Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.为什么酪氨酸激酶抑制剂无法治愈慢性髓性白血病。
Leukemia. 2021 Aug;35(8):2199-2204. doi: 10.1038/s41375-021-01272-8. Epub 2021 May 17.
3
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.TKI 剂量减少可有效维持慢性髓性白血病患者的主要分子缓解。
Br J Haematol. 2021 Apr;193(2):346-355. doi: 10.1111/bjh.17286. Epub 2020 Dec 24.
4
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.氟马替尼与伊马替尼治疗新诊断的慢性期慢性髓性白血病：一项III期、随机、开放标签、多中心FESTnd研究。
Clin Cancer Res. 2021 Jan 1;27(1):70-77. doi: 10.1158/1078-0432.CCR-20-1600. Epub 2020 Sep 14.
5
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.低剂量波纳替尼对于不耐受先前酪氨酸激酶抑制剂（TKI）的慢性髓性白血病患者而言是个不错的选择。
Am J Hematol. 2020 Oct;95(10):E260-E263. doi: 10.1002/ajh.25908. Epub 2020 Jul 7.
6
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.低剂量酪氨酸激酶抑制剂在治疗停止前使用不会损害慢性髓性白血病患者的无治疗缓解：一项回顾性研究的结果。
Cancer. 2020 Aug 1;126(15):3438-3447. doi: 10.1002/cncr.32940. Epub 2020 May 27.
7
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.慢性髓性白血病：诊断、治疗和监测的 2020 更新。
Am J Hematol. 2020 Jun;95(6):691-709. doi: 10.1002/ajh.25792. Epub 2020 Apr 10.
8
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
9
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).一项关于来那替尼与伊马替尼治疗新诊断的慢性期慢性髓性白血病患者的3期研究（RERISE）的长期数据。
Br J Haematol. 2020 Apr;189(2):303-312. doi: 10.1111/bjh.16381. Epub 2020 Feb 3.
10
Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.在慢性粒细胞白血病（CML）中，减量期间的分子监测可预测酪氨酸激酶抑制剂（TKI）停药后的复发情况。
Blood. 2020 Mar 5;135(10):766-769. doi: 10.1182/blood.2019003395.
Zotero 插件